Vyvanse vs Adderall for ADHD Treatment

Key Pharmacological Differences

The American Academy of Pediatrics recommends Vyvanse over immediate-release amphetamines in adolescents and young adults due to its lower abuse potential 1, 2, 3
Vyvanse is a prodrug that requires enzymatic hydrolysis in red blood cells to convert to active d-amphetamine, making it therapeutically inactive until metabolized in the body 2
Adderall is a mixture of immediate-release amphetamine salts (75% dextroamphetamine and 25% levoamphetamine) that is active upon ingestion 4, 5

Both medications demonstrate equivalent efficacy for core ADHD symptoms when dosed appropriately, with response rates of approximately 70% for either medication as monotherapy 6
Nearly 90% of patients respond to either medication if both are tried sequentially 7

The American Academy of Obstetrics and Gynecology recommends starting Vyvanse at 20-30 mg once daily in the morning, increasing by 10 mg weekly based on symptom response, with a maximum dose of 70 mg daily 8, 4
The Journal of the American Academy of Child and Adolescent Psychiatry recommends starting Adderall XR at 10 mg once daily, increasing by 5 mg weekly to a maximum of 50 mg daily 4, 5

Both medications carry similar fetal risks, including a possible small increased risk for gastroschisis, preeclampsia, and preterm birth when continued in the second half of pregnancy 8, 4, 5
Neither medication is associated with major congenital malformations or cardiac defects 4, 5

The American Academy of Pediatrics recommends choosing Vyvanse when there are concerns about diversion, substance use disorder, or the need for consistent all-day coverage 1, 2, 3
The Journal of the American Academy of Child and Adolescent Psychiatry recommends choosing Adderall when there is a need for flexible dosing throughout the day or immediate-release formulation is needed for titration or specific timing 7

The American Academy of Pediatrics explicitly recommends Vyvanse over immediate-release amphetamines in adolescents and young adults specifically because of concerns about diversion and abuse 9
The American Academy of Pediatrics suggests that Vyvanse is the preferred choice for a 19-year-old with ADHD due to its significantly lower abuse and diversion potential, which is critically important in this age group where stimulant misuse is a major concern 9

Screen for substance abuse symptoms before initiating treatment, as this is essential in adolescents and young adults 9
Monitor prescription-refill requests for signs of misuse or diversion 9

Do not assume both medications are interchangeable for a 19-year-old—the abuse potential difference is clinically significant in this age group 9
Do not prescribe immediate-release formulations when extended-release options are available, as they have higher abuse potential 9
Do not ignore the social context—college-age patients face significant peer pressure for stimulant diversion, making Vyvanse's abuse-deterrent properties particularly valuable 9